Rational antibiotic therapy and the position of ampicillin/sulbactam

International Journal of Antimicrobial Agents

Volumn 32, Issue 1, 2008, Pages 10-28

  Lode, Hartmut M ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Lactam; Lactamase inhibitor; Ampicillin; Antibiotic resistance; Sulbactam; Sultamicillin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; ANTIBIOTIC AGENT; AZTREONAM; BETA LACTAMASE INHIBITOR; BUDESONIDE; CEFOTAXIME; CEFOTETAN; CEFOXITIN; CEFUROXIME; CLAVULANIC ACID; CLINDAMYCIN; GENTAMICIN; IMIPENEM; LATAMOXEF; MEROPENEM; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON; SULTAMICILLIN; TAZOBACTAM; TIMENTIN; TOBRAMYCIN;

ABDOMINAL INFECTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC THERAPY; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL PNEUMONIA; BRONCHITIS; CLINICAL TRIAL; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG FORMULATION; DRUG INHIBITION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG STRUCTURE; DRUG USE; GONORRHEA; HOSPITAL INFECTION; HUMAN; OTITIS MEDIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PYELONEPHRITIS; RESPIRATORY TRACT INFECTION; SHORT SURVEY; SINUSITIS; SOFT TISSUE INFECTION; TONSILLITIS; TREATMENT INDICATION; URINARY TRACT INFECTION;

AMPICILLIN; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; HUMANS; SULBACTAM;

EID: 46549089742     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.02.004     Document Type: Short Survey

References (135)

1. Nathwani D., Wood M.J., and Penicillins. A current review of their clinical pharmacology and therapeutic use. Drugs 45 (1993) 866-894
2. Wright A.J. The penicillins. Mayo Clin Proc 74 (1999) 290-307
3. Williams J.D. Beta-lactamases and beta-lactamase inhibitors. Int J Antimicrob Agents 12 Suppl. 1 (1999) S3-S7
4. World Health Organisation. The world health report 2007: a safer future: global public health security in the 21st century. http://www.who.int/whr/2007/en/index.html [accessed 21 February 2008].
5. Bush K., Jacoby G.A., and Medeiros A.A. A functional classification scheme for beta-lactamases and its correlation with molecular structure. Antimicrob Agents Chemother 39 (1995) 1211-1233
6. Morrissey I., Robbins M., Viljoen L., and Brown D.F. Antimicrobial susceptibility of community-acquired respiratory tract pathogens in the UK during 2002/3 determined locally and centrally by BSAC methods. J Antimicrob Chemother 55 (2005) 200-208
7. Heilmann K.P., Rice C.L., Miller A.L., Miller N.J., Beekmann S.E., Pfaller M.A., et al. Decreasing prevalence of beta-lactamase production among respiratory tract isolates of Haemophilus influenzae in the United States. Antimicrob Agents Chemother 49 (2005) 2561-2564
8. Blosser-Middleton R., Sahm D.F., Thornsberry C., Jones M.E., Hogan P.A., Critchley I.A., et al. Antimicrobial susceptibility of 840 clinical isolates of Haemophilus influenzae collected in four European countries in 2000-2001. Clin Microbiol Infect 95 (2003) 431-436
9. Rennie R.P., and Ibrahim H. Antimicrobial resistance in Haemophilus influenzae: how can we prevent the inevitable? Commentary on antimicrobial resistance in H. influenzae based on data from the TARGETed surveillance program. Clin Infect Dis 41 Suppl. 4 (2005) S234-S238
10. European Antimicrobial Resistance Surveillance System (EARSS). Annual report 2005. http://www.rivm.nl/earss/news/index.jsp [accessed 21 February 2008].
11. Bush K. Beta-lactamase inhibitors from laboratory to clinic. Clin Microbiol Rev 1 (1988) 109-123
12. Williams J.D. Beta-lactamase inhibition and in vitro activity of sulbactam and sulbactam/cefoperazone. Clin Infect Dis 24 (1997) 494-497
13. Lode H. Role of sultamicillin and ampicillin/sulbactam in the treatment of upper and lower bacterial respiratory tract infections. Int J Antimicrob Agents 18 (2001) 199-209
14. Lees L., Milson J.A., Knirsch A.K., and Greenhalgh K. Sulbactam plus ampicillin: interim review of efficacy and safety for therapeutic and prophylactic use. Rev Infect Dis 8 Suppl. 5 (1986) S644-S650
15. Pitts N.E., Gilbert G.S., Knirsch A.K., and Noguchi Y. Worldwide clinical experience with sultamicillin. APMIS Suppl 5 (1989) 23-34
16. Friedel H.A., Campoli-Richards D.M., and Goa K.L. Sultamicillin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. Drugs 37 (1989) 491-522
17. Dajani A. Use of ampicillin/sulbactam and sultamicillin in pediatric infections: a re-evaluation. J Int Med Res 29 (2001) 257-269
18. Lode H., Hampel B., Bruckner G., and Koeppe P. The pharmacokinetics of sultamicillin. APMIS Suppl 5 (1989) 17-22
19. Lõivukene K., Sepp E., Adamson V., Mitt P., Kallandi U., Otter K., et al. Prevalence and antibiotic susceptibility of Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae in Estonian intensive care units in comparison with European data. Scand J Infect Dis 38 (2006) 1001-1008
20. Leesik H., Ani U., Juhani A., and Altraja A. Microbial pathogens of adult community-acquired pneumonia in Southern Estonia. Medicina (Kaunas) 42 (2006) 384-394
21. Programa Venezolano de Vigilancia de la Resistencia Bacteriana a los Antimicrobianos. http://www.provenra.org/whonetvenezuela/reportes.asp?accion=ver&tipo =r5 [accessed 9 March 2007].
22. Maciejewska K., Ke{ogonek}dzia A., Zienkiewicz J., Kiewlicz W., and Ziemlewski A. Study on the susceptibility of anaerobes isolated from blood of patients surgically treated within oral cavity to certain antibiotics and chemotherapeutic agents. Annales Academiae Medicae Gedanensis 36 (2006) 133-138
23. Torun M.M., Namal N., Demirci M., Bahar H., and Kocazeybek B. Pharyngeal carriage and antimicrobial resistance of Haemophilus influenzae in non-type-b-vaccinated healthy children attending day care centers in Turkey. Chemotherapy 53 (2007) 114-117
24. Brauers J., Bagel S., and Kresken M. Aktuelle Resistenzsituation bei bakteriellen Erregern von ambulant erworbenen Atemwegsinfektionen. Chemotherapie J 2 (2005) 45-53
25. Foulds G. Pharmacokinetics of sulbactam/ampicillin in humans: a review. Rev Infect Dis 8 Suppl. 5 (1986) S503-S511
26. Baltzer B., Binderup E., von Daehne W., Godtfredsen W.O., Hansen K., Nielsen B., et al. Mutual pro-drugs of beta-lactam antibiotics and beta-lactamase inhibitors. J Antibiot (Tokyo) 33 (1980) 1183-1192
27. Desager J.P., Costermans J., Van Nieuwenhuyze Y., and Harvengt C. Oral bioavailability of ampicillin and amoxycillin alone and bound in fixed proportions to sulbactam and clavulanic acid. J Int Med Res 17 (1989) 532-538
28. Hampel B., Lode H., Bruckner G., and Koeppe P. Comparative pharmacokinetics of sulbactam/ampicillin and clavulanic acid/amoxycillin in human volunteers. Drugs 359 Suppl. 7 (1988) 29-33
29. Campoli-Richards D.M., and Brogden R.N. Sulbactam/ampicillin. A review of its antibacterial activity, pharmacokinetic properties, and therapeutic use. Drugs 33 (1987) 577-609
30. Wildfeuer A., Mallwitz J., Gotthardt H., Hille E., Gruber H., Dahmen G., et al. Pharmacokinetics of ampicillin, sulbactam and cefotiam in patients undergoing orthopedic surgery. Infection 25 (1997) 258-262
31. Jones R.N., and Dudley M.N. Microbiologic and pharmacodynamic principals applied to the antimicrobial susceptibility testing of ampicillin/sulbactam: analysis of the correlations between in vitro test results and clinical response. Diagn Microbiol Infect Dis 28 (1997) 5-18
32. Drusano G.L. Pharmacokinetic optimization of β-lactams for the treatment of ventilator-associated pneumonia. Eur Respir Rev 16 (2007) 45-49
33. Nahata M.C., Vashi V.I., Swanson R.N., Messig M.A., and Chung M. Pharmacokinetics of ampicillin and sulbactam in pediatric patients. Antimicrob Agents Chemother 43 (1999) 1225-1229
34. Voelker M.S., Nightingale C.H., Quintiliani R., Lehmann C.H., Klimek J.J., and Hickingbotham J.M. Sultamicillin use in otitis media: penetration of sulbactam, a beta-lactamase inhibitor, and ampicillin into middle-ear fluid. Curr Ther Res Clin Exp 38 (1985) 738-745
35. Reilly J.S., Kim H.K., and Rohn D.D. Concentrations of sultamicillin in serum and middle ear fluid of children with chronic otitis media with effusion. Ann Otol Rhinol Laryngol 92 Suppl. 107 (1983) S44-S45
36. Sutton A.M., Turner T.L., Cockburn F., and McAllister T.A. Pharmacokinetic study of sulbactam and ampicillin administered concomitantly by intraarterial or intravenous infusion in the newborn. Rev Infect Dis 8 Suppl. 5 (1986) S518-S522
37. Ferreira J.B., Rapoport P.B., Sakano E., Kós A.O., Piltcher O.B., Pignatari S.S., et al. Efficacy and safety of sultamicillin (ampicillin/sulbactam) and amoxicillin/clavulanic acid in the treatment of upper respiratory tract infections in adults-an open-label, multicentric, randomized trial. Rev Bras Otorrinolaringol (Engl Ed) 72 (2006) 104-111 [in Portuguese]
38. Topuz B., Katircioǧlu O., Bayramoǧlu I., Ardiç F.N., and Erbudak H. Low dose sultamicillin in acute sinusitis. Infez Med 10 (2002) 45-48
39. Özbay B., and Uzun K. A comparison of ampicillin/sulbactam versus cefuroxime in the therapy of lower respiratory tract infections. Eur Respir J 10 (1997) 383S
40. Yanagihara K., Fukuda Y., Seki M., Izumikawa K., Higashiyama Y., Miyazaki Y., et al. Clinical comparative study of sulbactam/ampicillin and imipenem/cilastatin in elderly patients with community-acquired pneumonia. Intern Med 45 (2006) 995-999
41. Okimoto N., Kurihara T., Honda N., Asaoka N., Fujita K., Ohba H., et al. Clinical effect of ampicillin with beta-lactamase inhibitor (sulbactam/ampicillin) on community-acquired pneumonia in the elderly. J Infect Chemother 9 (2003) 183-186
42. Castellano M.A., and Maniatis T. Treatment of LRTIs: two antimicrobials compared. Infect Dis 15 (1998) 259-263
43. Ott S.R., Allewelt M., Lorenz J., Reimnitz P., Lode H., and The German Lung Abscess Study Group. Moxifloxacin vs. ampicillin/sulbactam in aspiration pneumonia and primary lung abscess. Infection 36 (2008) 23-30
44. Allewelt M., Schüler P., Bölcskei P.L., Mauch H., Lode H., and Study Group on Aspiration Pneumonia. Ampicillin + sulbactam vs clindamycin ± cephalosporin for the treatment of aspiration pneumonia and primary lung abscess. Clin Microbiol Infect 10 (2004) 163-170
45. Kadowaki M., Demura Y., Mizuno S., Uesaka D., Ameshima S., Miyamori I., et al. Reappraisal of clindamycin IV monotherapy for treatment of mild-to-moderate aspiration pneumonia in elderly patients. Chest 127 (2005) 1276-1282
46. Betrosian A.P., Frantzeskaki F., Xanthaki A., and Georgiadis G. High-dose ampicillin-sulbactam as an alternative treatment of late-onset VAP from multidrug-resistant Acinetobacter baumannii. Scand J Infect Dis 39 (2007) 38-43
47. Wood G.C., Hanes S.D., Croce M.A., Fabian T.C., and Boucher B.A. Comparison of ampicillin-sulbactam and imipenem-cilastatin for the treatment of Acinetobacter ventilator-associated pneumonia. Clin Infect Dis 34 (2002) 1425-1430
48. Grayson M.L., Gibbons G.W., Habershaw G.M., Freeman D.V., Pomposelli F.B., Rosenblum B.I., et al. Use of ampicillin/sulbactam versus imipenem/cilastatin in the treatment of limb-threatening foot infections in diabetic patients. Clin Infect Dis 18 (1994) 683-693
49. Weigelt J.A. A comparison of ampicillin/sulbactam and cefoxitin in the treatment of bacterial skin and skin-structure infections. Adv Ther 11 (1994) 183-191
50. Chan J.C. Ampicillin/sulbactam versus cefazolin or cefoxitin in the treatment of skin and skin-structure infections of bacterial etiology. Adv Ther 12 (1995) 139-146
51. Löffler L., Bauernfeind A., Keyl W., Hoffstedt B., Piergies A., and Lenz W. An open, comparative study of sulbactam plus ampicillin vs. cefotaxime as initial therapy for serious soft tissue and bone and joint infections. Rev Infect Dis 8 Suppl. 5 (1986) S593-S598
52. McKinnon P.S., and Neuhauser M.M. Efficacy and cost of ampicillin-sulbactam and ticarcillin-clavulanate in the treatment of hospitalized patients with bacterial infections. Pharmacotherapy 19 (1999) 724-733
53. Ozbek C., Aygenc E., Unsal E., and Ozdem C. Peritonsillar abscess: a comparison of outpatient i.m. clindamycin and inpatient i.v. ampicillin/sulbactam following needle aspiration. Ear Nose Throat J 84 (2005) 366-368
54. Talan D.A., Summanen P.H., and Finegold S.M. Ampicillin/sulbactam and cefoxitin in the treatment of cutaneous and other soft-tissue abscesses in patients with or without histories of injection drug abuse. Clin Infect Dis 31 (2000) 464-471
55. Harkless L., Boghossian J., Pollak R., Caputo W., Dana A., and Gray S. An open-label, randomized study comparing efficacy and safety of intravenous piperacillin/tazobactam and ampicillin/sulbactam for infected diabetic foot ulcers. Surg Infect (Larchmt) 6 (2005) 27-40
56. Stridde E., Meyne K., Kluth-Pepper B., and Ziegler D. Sulbactam/ampicillin or clindamycin in the treatment of foot infections in diabetic patients with polyneuropathy. Exp Clin Endocrinol Diabetes 108 (2000) S124
57. Erstad Jr. B.L., McIntyre Jr. Ke., and Mills J.L. Prospective, randomized comparison of ampicillin/sulbactam and cefoxitin for diabetic foot infections. Vasc Surg 31 (1997) 419-426
58. Lipsky B.A., Baker P.D., Landon G.C., and Fernau R. Antibiotic therapy for diabetic foot infections: comparison of two parenteral-to-oral regimens. Clin Infect Dis 24 (1997) 643-648
59. Holzheimer R.G., and Dralle H. Antibiotic therapy in intra-abdominal infections-a review on randomised clinical trials. Eur J Med Res 6 (2001) 277-291
60. Yellin A.E., Heseltine P.N., Berne T.V., Appleman M.D., Gill M.A., Riggio C.E., et al. The role of Pseudomonas species in patients treated with ampicillin and sulbactam for gangrenous and perforated appendicitis. Surg Gynecol Obstet 161 (1985) 303-307
61. Walker A.P., Nichols R.L., Wilson R.F., Bivens B.A., Trunkey D.D., Edmiston Jr. C.E., et al. Efficacy of a beta-lactamase inhibitor combination for serious intraabdominal infections. Ann Surg 217 (1993) 115-121
62. Wong P.F., Gilliam A.D., Kumar S., Shenfine J., O'Dair G.N., and Leaper D.J. Antibiotic regimens for secondary peritonitis of gastrointestinal origin in adults. Cochrane Database Syst Rev (2005) CD004539
63. Study Group of Intra-Abdominal Infections. A randomized controlled trial of ampicillin plus sulbactam versus gentamicin and clindamycin in the treatment of intraabdominal infections: a preliminary report. Rev Infect Dis 8 Suppl. 5 (1986) S583-S588
64. Gall S., and Koukol D.H. Ampicillin/sulbactam vs. clindamycin/gentamicin in the treatment of postpartum endometritis. J Reprod Med 41 (1996) 575-580
65. Stovall T.G., Thorpe Jr. E.M., and Ling F.W. Treatment of post-cesarean section endometritis with ampicillin and sulbactam or clindamycin and gentamicin. J Reprod Med 38 (1993) 843-848
66. Martens M.G., Faro S., Hammill H.A., Smith D., Riddle G., and Maccato M. Ampicillin/sulbactam versus clindamycin in the treatment of postpartum endomyometritis. South Med J 83 (1990) 408-413
67. Martens M.G., Faro S., Hammill H.A., Smith D., Riddle G., and Maccato M. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of post-cesarean section endometritis. Diagn Microbiol Infect Dis 12 Suppl. 4 (1989) 189S-194S
68. McGregor J.A., Crombleholme W.R., Newton E., Sweet R.L., Tuomala R., and Gibbs R.S. Randomized comparison of ampicillin-sulbactam to cefoxitin and doxycycline or clindamycin and gentamicin in the treatment of pelvic inflammatory disease or endometritis. Obstet Gynecol 83 (1994) 998-1004
69. McGregor J.A., and Christensen F.B. A comparison of ampicillin plus sulbactam versus clindamycin and gentamicin for treatment of postpartum infection. Suppl Int J Gynecol Obstet 2 (1989) 35-39
70. Hemsell D.L., Bawdon R.E., Hemsell P.G., Nobles B.J., and Heard M.C. Single-agent therapy for acute pelvic inflammatory disease: sulbactam/ampicillin versus cefoxitin. J Int Med Res 18 Suppl. 4 (1990) 85D-89D
71. Crombleholme W.R., Ohm-Smith M., Robbie M.O., DeKay V., and Sweet R.L. Ampicillin/sulbactam versus metronidazole-gentamicin in the treatment of soft tissue pelvic infections. Am J Obstet Gynecol 156 (1987) 507-512
72. Crombleholme W., Landers D., Ohm-Smith M., Robbie M.O., Hadley W.K., DeKay V., et al. Sulbactam/ampicillin versus metronidazole/gentamicin in the treatment of severe pelvic infections. Drugs 31 Suppl. 2 (1986) 11-13
73. Hellmann N.S., Nsubuga P.S., Baingana-Baingi D.J., Desmond-Hellmann S.D., Mbidde E.K., Granowitz C.B., et al. Single-dose ampicillin/sulbactam versus ceftriaxone as treatment for uncomplicated gonorrhoea in a Ugandan STD clinic population with a high prevalence of PPNG infection. J Trop Med Hyg 98 (1995) 95-100
74. Baddour L.M., Busby L., Shapiro E., Cox K.B., Glassco S., and Johnson J.K. Evaluation of treatment with single-dose ampicillin/sulbactam with probenecid or ceftriaxone in patients with uncomplicated gonorrhea. Sex Transm Dis 19 (1992) 341-345
75. Ngeow Y.F., Ramachandran S., and Cheong Y.M. Treatment of gonorrhea with sulbactam/ampicillin. Sex Transm Dis 18 (1991) 192-194
76. Kim J.H., Choic K.H., Kin Y.T., and Yang I.S. Treatment of infections due to multiresistant Neisseria gonorrhoeae with sulbactam/ampicillin. Rev Infect Dis 8 Suppl. 5 (1986) S599-S603
77. Farthing C., Thin R.N., Smith S., and Phillips I. Two regimens of sultamicillin in treating uncomplicated gonorrhoea. Genitourin Med 61 (1985) 44-47
78. Atia W.A., Emmerson A.M., and Holmes D. Sultamicillin in the treatment of gonorrhoea caused by penicillin sensitive and penicillinase producing strains of Neisseria gonorrhoeae. Br J Vener Dis 59 (1983) 293-297
79. Schütz W. Efficacy and safety of sultamicillin (750 mg bid) compared with amoxycillin/clavulanate (625 mg tid) in patients with uncomplicated urinary tract infections. Int J Antimicrob Agents 6 Suppl. 1 (1996) S55-S59
80. Naber K.G., and Wittenberger R. Sultamicillin versus trimethoprim/sulfamethoxazole in the treatment of urinary tract infections. APMIS Suppl 5 (1989) 57-62
81. Perepanova T.S., Kotliarova G.A., Kondrat'eva E.M., Siniukhin V.N., and Safin R.N. Sulbactam/ampicillin in the treatment and prevention of urologic diseases. Antibiot Khimioter 38 (1993) 49-55 [in Russian]
82. Perepanova T.S., Kotliarova G.A., Kondrat'eva E.M., Siniukhin V.N., Derevianko I.I., and Safin R.N. The use of ampicillin/sulbactam (Unasyn) in treating inflammatory urological diseases. Antibiot Khimioter 36 (1991) 21-25 [in Russian]
83. Fukatsu H., Noonmura H., Miyagawa Y., Waki M., Hatano Y., Hiraiwa S., et al. Clinical evaluation of sultamicillin in the treatment of urinary tract infections. Hinyokika Kiyo 36 (1990) 861-867 [in Japanese]
84. Kawada Y. Sultamicillin in the treatment of urinary tract infections. APMIS Suppl 5 (1989) 63-67
85. Levin A.S. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 8 (2002) 144-153
86. Levin A.S., Levy C.E., Manrique A.E., Medeiros E.A., and Costa S.F. Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam. Int J Antimicrob Agents 21 (2003) 58-62
87. Kanra G. Experience with ampicillin/sulbactam in severe infections. J Int Med Res 30 Suppl. 1 (2002) 20A-30A
88. Biolcati A.H. An open comparative study of the efficacy and safety of sultamicillin versus cefaclor in the treatment of acute otitis media in children. J Int Med Res 20 Suppl. 1 (1992) 31A-43A
89. Raillard P., Kose G., Ozkan H., Hasanoglu A., Firat S., and Feiner C. Worldwide pediatric experience with low-dose sultamicillin oral suspension. Curr Ther Res Clin Exp 55 (1994) 601-613
90. Karlidaǧ T., Kaygusuz I., Gök U., Yalçin S., Keleş E., and Oztürk L. The efficacy of combining antibiotic treatment with topical intranasal steroid administration in the treatment of chronic otitis media with effusion. Kulak Burun Bogaz Ihtis Derg 9 (2002) 257-262 [in Turkish]
91. Lopez E.L., and Rivas N.A. Clinical use of sultamicillin (ampicillin/sulbactam) in children. Pediatr Infect Dis J 17 Suppl. 3 (1998) S12-S14
92. Gómez Campderá J., Ruiz Conde A., Navarro Gómez M.L., Calle G., and Rodriguez Fernandez. Sultamicilina frente a amoxicilina/ácido clavulánco en el tratamiento de las neumonías en la infancia. Acta Pediatr Esp 58 (2000) 7-11
93. Daniscovicova-Nogeova A., Galova K., Sufliarska S., Krizan S., Kukova Z., and Krupova I. Cefuroxime-axetil versus ampicillin-sulbactam in therapy of community-acquired pneumonia: a randomized multicenter study in 149 children. Antiinfect Drugs Chemother 16 (1999) 219-220
94. Airede A'KI, Jalo I., Weerasinghe H.D., Bello M., and Adeyemi S. Observations on oral sultamicillin/Unasyn CP-45899 therapy of neonatal infections. Int J Antimicrob Agents 8 (1997) 103-107
95. Kulhanjian J., Dunphy M.G., Hamstra S., Levernier K., Rankin M., Petru A., et al. Randomized comparative study of ampicillin/sulbactam vs. ceftriaxone for treatment of soft tissue and skeletal infections in children. Pediatr Infect Dis J 8 (1989) 605-610
96. Goldfarb J., Aronoff S.C., Jaffe A., Reed M.D., and Blumer J.L. Sultamicillin in the treatment of superficial skin and soft tissue infections in children. Antimicrob Agents Chemother 31 (1987) 663-664
97. Rush D.E., Abdel-Haq N., Zhu J.F., Aamar B., and Malian M. Clindamycin versus Unasyn in the treatment of facial cellulitis of odontogenic origin in children. Clin Pediatr (Phila) 46 (2007) 154-159
98. Abdel-Haq N.M., Harahsheh A., and Asmar B.L. Retropharyngeal abscess in children: the emerging role of group A beta hemolytic streptococcus. South Med J 99 (2006) 927-931
99. Tanir G., Tonbul A., Tuygun N., Aydemir C., and Ertan U. Soft tissue infections in children: a retrospective analysis of 242 hospitalized patients. Jpn J Infect Dis 59 (2006) 258-260
100. Cengiz A.B., Kara A., Kanra G., Seçmeer G., Ceyhan M., and Ozen M. Acute neck infections in children. Turk J Pediatr 46 (2004) 153-158
101. Azimi P.H., Barson W.J., Janner D., Swanson R., and UNASYN Pediatric Study Group. Efficacy and safety of ampicillin/sulbactam and cefuroxime in the treatment of serious skin and skin structure infections in pediatric patients. Pediatr Infect Dis J 18 (1999) 609-613
102. Aronoff S.C., Scoles P.V., Makley J.T., Jacobs M.R., Blumer J.L., and Kalamchi A. Efficacy and safety of sequential treatment with parenteral sulbactam/ampicillin and oral sultamicillin for skeletal infections in children. Rev Infect Dis 8 Suppl. 5 (1986) S639-S643
103. Collins M.D., Dajani A.S., Kim K.S., King D.R., Kaplan S.L., Azimi P.H., et al., The Multicenter Group. Comparison of ampicillin/sulbactam plus aminoglycoside vs. ampicillin plus clindamycin plus aminoglycoside in the treatment of intraabdominal infections in children. Pediatr Infect Dis J 17 Suppl. 3 (1998) S15-S18
104. Smyth E.T., and Emmerson A.M. Surgical site infection surveillance. J Hosp Infect 45 (2000) 173-184
105. Tang R., Chen H.H., Wang Y.L., Changchien C.R., Chen J.S., Hsu K.C., et al. Risk factors for surgical site infection after elective resection of the colon and rectum: a single-center prospective study of 2,809 consecutive patients. Ann Surg 234 (2001) 181-189
106. Yoshida S., Masuda H., Yokoyama M., Kobayashi T., Kawakami S., and Kihara K. Absence of prophylactic antibiotics in minimum incision endoscopic urological surgery (MEUS) of adrenal and renal tumors. Int J Urol 14 (2007) 384-387
107. Dervisoglou A., Tsiodras S., Kanellakopoaulou K., Pinis S., Galanakis N., Pierakakis S., et al. The value of chemoprophylaxis against Enterococcus species in elective cholecystectomy: a randomized study of cefuroxime vs ampicillin-sulbactam. Arch Surg 141 (2006) 1162-1167
108. Kato D., Maezawa K., Yonezawa I., Iwase Y., Ikeda H., and Nozawa M. Randomized prospective study on prophylactic antibiotics in clean orthopedic surgery in one ward for 1 year. J Orthop Sci 11 (2006) 20-27
109. Wong G.K., Poon W.S., Lyon D., and Wai S. Cefepime vs. ampicillin/sulbactam and aztreonam as antibiotic prophylaxis in neurosurgical patients with external ventricular drain: result of a prospective randomized controlled clinical trial. J Clin Pharm Ther 31 (2006) 231-235
110. Seven H., Sayin I., and Turgut S. Antibiotic prophylaxis in clean neck dissections. J Laryngol Otol 118 (2004) 213-216
111. Yerdel M. Effect of single-dose prophylactic ampicillin and sulbactam on wound infection after tension-free inguinal hernia repair with polypropylene mesh: the randomized, double-blind, prospective trial. Ann Surg 233 (2001) 26-33
112. Zhu X.L., Wong W.K., Yeung W.M., Mo P., Tsang C.S., Pang K.H., et al. A randomized, double-blind comparison of ampicillin/sulbactam and ceftriaxone in the prevention of surgical-site infections after neurosurgery. Clin Ther 23 (2001) 1281-1291
113. Fujiwara K., Suda S., and Ebina T. Efficacy of antibiotic prophylaxis in clean neurosurgical operations: a comparison of seven-day versus one-day administration. No Shinkei Geka 28 (2000) 423-427 [in Japanese]
114. Spinnato J.A., Youkilis B., Cook V.D., Pietrantoni M., Clark A.L., and Gall S.A. Antibiotic prophylaxis at Cesarean delivery. J Matern Fetal Med 9 (2000) 348-350
115. Warnke J.P., Wildfeuer A., Eibel G., Pfaff G., and Klammer A. Pharmacokinetics of ampicillin/sulbactam in patients undergoing spinal microneurosurgical procedures. Int J Clin Pharmacol Ther 36 (1998) 253-257
116. Bracero L.A. Ampicillin/sulbactam versus cefotetan for the prevention of infection following cesarean delivery in high-risk patients: a randomized double-blind trial. Gynecol Obstet Invest 44 (1997) 21-25
117. Noyes N., Berkeley A.S., Freedman K., and Ledger W. Incidence of postpartum endomyometritis following single-dose antibiotic prophylaxis with either ampicillin/sulbactam, cefazolin, or cefotetan in high-risk cesarean section patients. Infect Dis Obstet Gynecol 6 (1998) 220-223
118. Benson J.M., Nahata M.C., and Sulbactam/ampicillin. a new beta-lactamase inhibitor/beta-lactam antibiotic combination. Drug Intell Clin Pharm 22 (1988) 534-541
119. Unasyn US Physician Prescribing Information LAB-0017-4.0 Revised April 2007. http://www.pfizer.com/products/rx/rx_product_unasyn.jsp [accessed 21 February 2008].
120. Kuijper E.J., Coignard B., Tull P., and ESCMID Study Group for Clostridium difficile; EU Member States; European Centre for Disease Prevention and Control. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 12 Suppl. 6 (2006) 2-18
121. Berg P., and Hahn E.G. Hepatotoxic reactions induced by beta-lactamase inhibitors. Eur J Med Res 6 (2001) 535-542
122. See T.T., and Lee S.P. Cholestasis associated with ampicillin/sulbactam therapy: a case report. J Intern Med Taiwan 17 (2006) 87-90
123. Gyssens I.C. International guidelines for infectious diseases: a practical guide. Neth J Med 63 (2005) 291-299
124. Mazuski J.E., Sawyer R.G., Nathens A.B., DiPiro J.T., Schein M., Kudsk K.A., et al. The Surgical Infection Society guidelines on antimicrobial therapy for intra-abdominal infections: an executive summary. Surg Infect (Larchmt) 3 (2002) 161-173
125. Solomkin J.S., Mazuski J.E., Baron E.J., Sawyer R.G., Nathens A.B., DiPiro J.T., et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 37 (2003) 997-1005
126. Hsueh P.R., and Hawkey P.M. Consensus statement on antimicrobial therapy of intra-abdominal infections in Asia. Int J Antimicrob Agents 30 (2007) 129-133
127. Centers for Disease Control and Prevention (CDC). Sexually transmitted diseases treatment guidelines, 2006. MMWR Morb Mortal Wkly Rep 2006; 55:RR-11.
128. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med 171 (2005) 388-416
129. Luna C.M., Monteverde A., Rodríguez A., Apezteguia C., Zabert G., Ilutovich S., et al. Clinical guidelines for the treatment of nosocomial pneumonia in Latin America: an interdisciplinary consensus document. Recommendations of the Latin American Thoracic Society. Arch Bronconeumol 41 (2005) 439-456 [in Spanish]
130. Mandell L.A., Wunderink R.G., Anzueto A., Bartlett J.G., Campbell G.D., Dean N.C., et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 44 Suppl. 2 (2007) S27-S72
131. Asociación Colombiana de Neumología y Cirugía de Tórax; Asociación Colombiana de Infectología; Asociación Colombiana de Medicina Interna. Recomendaciones para el diagnóstico, tratamiento y prevención de la neumonía adquirida en la comunidad en adultos. Revista Colombiana de Neumología 15 Suppl. 3 (2003) S25
132. Woodhead M., Blasi F., Ewig S., Huchon G., leven M., Ortqvist A., et al. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J 26 (2005) 1138-1180
133. Stevens D.L., Bisno A.L., Chambers H.F., Everett E.D., Dellinger P., Goldstein E.J., et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis 41 (2005) 1373-1406
134. Lipsky B.A., Berendt A.R., Deery H.G., Embil J.M., Joseph W.S., Karchmer A.W., et al. Diagnosis and treatment of diabetic foot infections. Clin Infect Dis 39 (2004) 885-910
135. Dellit T.H., Owens R.C., McGowan Jr. J.E., Gerding D.N., Weinstein R.A., Burke J.P., et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 44 (2007) 159-177